Ratings BeiGene, Ltd. Deutsche Boerse AG

Equities

49B

KYG1146Y1017

Real-time Estimate Tradegate Other stock markets 12:21:28 18/05/2024 am IST			5-day change	1st Jan Change
12.15 ^EUR	+2.97%		+2.59%	-4.03%

14/05	BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	CI
09/05	Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company is in a robust financial situation considering its net cash and margin position.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BEIGENE, LTD.	-4.03%	17.89B	-
VERTEX PHARMACEUTICALS INCORPORATED	+9.26%	114B	B+
REGENERON PHARMACEUTICALS, INC.	+11.39%	104B	B+
BIONTECH SE	-13.85%	22.41B	B+
ARGENX SE	-1.05%	22.28B	B
GENMAB A/S	-5.29%	19.07B	A-
WUXI APPTEC CO., LTD.	-38.29%	18B	A-
NEUROCRINE BIOSCIENCES, INC.	+7.73%	14.28B	C+
SAREPTA THERAPEUTICS, INC.	+34.71%	12.55B	C+
LEGEND BIOTECH CORPORATION	-25.38%	8.45B	D

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes